Paclitaxel liposome with anti–HER-2 drugs as first-line therapy for recurrent/metastatic HER-2–positive breast cancer: a real-world study.
| Publicado en: | Holistic Integrative Oncology Vol. 5; no. 1; pp. 1 - 12 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Springer Nature
8/11/2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=196093787&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 196093787 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 27314529 N50T jtl: Holistic Integrative Oncology issn: 27314529 maglogo: N pubinfo: dt: 8/11/2026 vid: 5 iid: 1 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 196093787 196093787 196093787 10.1007/s44178-026-00283-8 196093787 ppf: 1 ppct: 11 formats: tig: atl: Paclitaxel liposome with anti–HER-2 drugs as first-line therapy for recurrent/metastatic HER-2–positive breast cancer: a real-world study. aug: au: Yue, Jian Zhang, Jin Wang, Shusen Zhang, Lili Zeng, Xiaohua Li, Huiping Ma, Fei Hui, Zhouguang affil: https://ror.org/02drdmm93 Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China sug: subj: Breast Neoplasms Drug Therapy Breast Neoplasms Familial and Genetic HER-2-neu Oncogene Drug Effects Neoplasm Recurrence, Local Drug Therapy Neoplasm Metastasis Drug Therapy Paclitaxel Therapeutic Use Drug Delivery Systems Antibodies, Monoclonal Therapeutic Use Antineoplastic Agents, Combined Therapeutic Use Salvage Therapy Drug Efficacy Evaluation Patient Safety Evaluation Human Female Cancer Patients Retrospective Design Record Review Progression-Free Survival Breast Neoplasms Prognosis Hormone Receptor Positive Breast Neoplasms Drug Therapy Trastuzumab Therapeutic Use Tyrosine Kinase Inhibitors Therapeutic Use After Care Overall Survival Confidence Intervals Descriptive Statistics Paclitaxel Adverse Effects Antineoplastic Agents, Combined Adverse Effects Signs and Symptoms, Digestive Chemically Induced Hepatotoxicity Neurotoxicity Syndromes Chemotherapy, Cancer Funding Source Multivariate Analysis Middle Age Kaplan-Meier Estimator Cox Proportional Hazards Model Data Analysis Software Middle Aged: 45-64 years Female pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|